Clinical Trial

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Completed Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase Ib/II, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of JS015 combination therapy in patients with advanced solid tumors. The Recommended dose for phase II trial （RP2D） will be determined based on the safety, tolerability, pharmacokinetics and efficacy.
Protocol Amendment History 4 changes
critical Trial completed 2026-08-13
notable Enrollment reduced: 186 -> 66 participants 2026-08-13
notable Primary completion pushed: 2025-11-01 -> 2026-05-28 2026-08-13
minor Completion pushed: 2026-01-28 -> 2026-05-28 2026-08-13
Trial Details
NCT Number NCT06139211
Lead Sponsor Shanghai Junshi Bioscience Co., Ltd.
Collaborators: Sponsor GmbH
Conditions Advanced Solid Tumor
Enrollment 66 participants
Start Date 2023-12-06
Primary Completion 2026-05-28 (estimated)
Study Completion 2026-05-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-12